Anti-Human CD123 (IL-3Rα) Antibody, Clone 6H6, FITC

Antibodies

Mouse monoclonal IgG1 antibody against human, rhesus, sooty mangabey CD123 (IL-3Rα), FITC-conjugated

Catalog	#60110FI	100 Tests	5 µL/test
	#60110FI.1	25 Tests	5 µL/test

STEMCELL™ TECHNOLOGIES
Scientists Helping Scientists™ | WWW.STEMCELL.COM
TOLL FREE PHONE 1 800 667 0322 • PHONE +1 604 877 0713
INFO@STEMCELL.COM • TECHSUPPORT@STEMCELL.COM
FOR GLOBAL CONTACT DETAILS VISIT OUR WEBSITE

Product Description

The 6H6 antibody reacts with human CD123 (IL-3 receptor subunit α), an ~70 kDa type I transmembrane glycoprotein belonging to the type I cytokine receptor family (type 5 subfamily) and the immunoglobulin (Ig) superfamily. CD123 constitutes the ligand-binding α chain of the heterodimeric IL-3 receptor. CD123 binds IL-3 with low affinity per se, but when associated with CD131 (the signal-transducing β chain of the receptor), high-affinity binding of IL-3 is observed. CD123 is expressed by hematopoietic progenitor cells, endothelial cells, basophils, eosinophils, mast cells, monocytes, macrophages, dendritic cells, megakaryocytes, a subset of B cells, and by neutrophils if cultured in the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF). IL-3 binding to CD123 stimulates proliferation, differentiation, and viability of hematopoietic cells. CD123 is highly expressed in malignancies such as acute leukemia. The 6H6 antibody does not inhibit binding of IL-3 to either CD123 or the IL-3 receptor.

Target Antigen Name:	CD123 (IL-3Rα)
Alternative Names:	hIL-3Ra, IL3R, IL3RAX, IL3RAY, IL3RX, IL3RY, IL-3Ra, IL-3 receptor alpha SP2 isoform, Interleukin-3 Receptor alpha, MGC34174
Gene ID:	3563
Species Reactivity:	Human, Rhesus, Sooty Mangabey
Host Species:	Mouse (BALB/c)
Clonality:	Monoclonal
Clone:	6H6
Isotype:	IgG1, kappa
Immunogen:	COS cells transfected with a cDNA encoding the human IL-3Rα chain
Conjugate:	FITC (Fluorescein isothiocyanate)

Applications

Verified:	FC
Reported:	FC
Special Applications:	This antibody clone has been verified for purity assessments of cells isolated with EasySep™ kits, including EasySep™ Human Plasmacytoid DC Enrichment Kit (Catalog #19062) and EasySep™ Human Basophil Enrichment Kit (Catalog #19069).

Abbreviations: CellSep: Cell separation; ChIP: Chromatin immunoprecipitation; FA: Functional assay; FACS: Fluorescence-activated cell sorting; FC: Flow cytometry; ICC: Immunocytochemistry; IF: Immunofluorescence microscopy; IHC: Immunohistochemistry; IP: Immunoprecipitation; RIA: Radioimmunoassay; WB: Western blotting

Properties

Formulation:	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide and 0.2% (w/v) bovine serum albumin
Purification:	The antibody was purified by affinity chromatography and conjugated with FITC under optimal conditions. The solution is free of unconjugated FITC.
Stability and Storage:	Product stable at 2 - 8°C when stored undiluted. Do not freeze. Protect product from prolonged exposure to light. For product expiry date, please contact techsupport@stemcell.com.
Directions for Use:	For flow cytometry, the suggested use of this antibody is ≤ 5 µL per 1 x 10^6 cells in 100 µL. It is recommended that the antibody be titrated for optimal performance for each application.

Data



(A) Flow cytometry analysis of human peripheral blood mononuclear cells (PBMCs; gated on lymphocytes) labeled with Anti-Human CD123 (IL-3Rα) Antibody, Clone 6H6, FITC and Anti-Human CD45RO Antibody, Clone UCHL1, PE (Catalog #60097PE).
(B) Flow cytometry analysis of human PBMCs (gated on lymphocytes) labeled with Mouse IgG1, kappa Isotype Control Antibody, Clone MOPC-21, FITC (Catalog #60070FI) and Anti-Human CD45RO Antibody, Clone UCHL1, PE.

Related Products

For a complete list of antibodies, including other conjugates, sizes and clones, as well as related products available from STEMCELL Technologies, please visit our website at www.stemcell.com/antibodies or contact us at techsupport@stemcell.com.

References

1. Breton G et al. (2015) Circulating precursors of human CD1c+ and CD141+ dendritic cells. J Exp Med 212(3): 401–13. (FC)
2. Lee J et al. (2015) Restricted dendritic cell and monocyte progenitors in human cord blood and bone marrow. J Exp Med 212(3): 385–99. (FACS, FC)
3. Greer AM et al. (2014) Accumulation of BDCA1+ dendritic cells in interstitial fibrotic lung diseases and Th2-high asthma. PLoS One 9(6): e99084. (FC)
4. Kivisäkk P et al. (2014) Effect of natalizumab treatment on circulating plasmacytoid dendritic cells: A cross-sectional observational study in patients with multiple sclerosis. PLoS One 9(7): e103716. (FC)
5. Royle CM et al. (2014) HIV-1 and HIV-2 differentially mature plasmacytoid dendritic cells into IFN-producing cells or APCs. J Immunol 193(7): 3538–48. (FC)
6. Hwang K et al. (2013) Immunohistochemical analysis of CD123, CD56 and CD4 for the diagnosis of minimal bone marrow involvement by blastic plasmacytoid dendritic cell neoplasm. Histopathology 62(5): 764–70. (IHC)
7. Manuel SL et al. (2013) An altered maturation and adhesion phenotype of dendritic cells in diseased individuals compared to asymptomatic carriers of human T cell leukemia virus type 1. AIDS Res Hum Retroviruses 29(9): 1273–85. (FC)
8. Chen SC et al. (2010) Expression of chemokine receptor CXCR3 by lymphocytes and plasmacytoid dendritic cells in human psoriatic lesions. Arch Dermatol Res 302(2): 113–23. (IHC)
9. Martín-Gayo E et al. (2010) Plasmacytoid dendritic cells resident in human thymus drive natural Treg cell development. Blood 115(26): 5366–75. (FC, IF, IHC)
10. Xu W et al. (2007) Epithelial cells trigger frontline immunoglobulin class switching through a pathway regulated by the inhibitor SLPI. Nat Immunol 8(3): 294–303. (ICC, IF, IHC)
11. Jaye DL et al. (2006) Expression of the plasmacytoid dendritic cell marker BDCA-2 supports a spectrum of maturation among CD4+ CD56+ hematodermic neoplasms. Mod Pathol 19(12): 1555–62. (IHC)
12. Herling M et al. (2003) TCL1 expression in plasmacytoid dendritic cells (DC2s) and the related CD4+ CD56+ blastic tumors of skin. Blood 101(12): 5007–09. (IHC)
13. Rapoport AP et al. (1996) Mutational analysis of the alpha subunit of the human interleukin-3 receptor. Blood 87(1): 112–22. (FC, ICC, IF)
14. Sun Q et al. (1996) Monoclonal antibody 7G3 recognizes the N-terminal domain of the human interleukin-3 (IL-3) receptor α-chain and functions as a specific IL-3 receptor antagonist. Blood 87(1): 83–92. (FA, IP, WB)